CRISPR therapy takes on Drug-Resistant lung cancer in liver

NCT ID NCT07461727

Not yet recruiting Disease control Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests a new gene-editing drug called EDB-102 in 15 people with advanced non-small cell lung cancer that has spread to the liver and no longer responds to standard targeted therapy. The drug uses CRISPR technology to target and disable a specific cancer-causing gene mutation. The main goal is to check safety and find the right dose.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: EDB-102 (CRISPR-Cas9 gene-editing therapy)
What this could lead to: If it works, this could point toward a new treatment option for patients with a specific type of lung cancer that has spread to the liver and stopped responding to current drugs.
What could go wrong: This is a very early, small Phase 1 trial with only 15 participants, so safety and effectiveness are not yet proven. The therapy may cause side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EGFR GENE MUTATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EGFR GENE MUTATION EGFR L858R LIVER METASTASES METASTATIC NON-SMALL CELL LUNG CANCER NON-SMALL CELL LUNG CANCER

More trials for these conditions

Other studies related to the condition(s) this trial covers.